Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6692355 | 0.98 | ADRA2A (0.49) | CA1CA2ADRA2APPARAFFAR1 | |
| SCHEMBL6691557 | 0.90 | FFAR1 (0.54) | ADRA2APPARAFFAR1TRPA1P2RX1 | |
| SCHEMBL1241369 | 0.90 | CA1 (0.45) | CA1CA2ADRA2APPARAFFAR1 | |
| Ammonia Solution, Strong SCHEMBL6691468 | 0.84 | LMNA (0.50) | CA1CA2PPARAFFAR1ALDH1A1 | |
| SCHEMBL6694323 | 0.82 | PTPN1 (0.50) | CA1CA2PPARATRPA1TRPV1 | |
| SCHEMBL6692367 | 0.81 | AGER (0.50) | ADRA2APPARAFFAR1TRPA1P2RX1 | |
| SCHEMBL6690731 | 0.81 | CA1 (0.54) | CA1CA2PPARATRPV1CYP1A2 | |
| SCHEMBL5184746 | 0.80 | CA1 (0.70) | CA1CA2TRPV1EPHX2NR1H4 | |
| SCHEMBL6700869 | 0.78 | P2RX1 (0.46) | CA2TRPA1TRPV1P2RX1CYP1A2 | |
| SCHEMBL7345712 | 0.76 | FFAR1 (0.68) | CA1CA2ADRA2APPARAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009973-A1 | Phenylenediamine derivatives N-substituted with benzyl- or heteroarylmethyl- groups | 4SC AG (DE) | 2004-01-15 | — | — | US | disclosed |
| WO-2003076388-A2 | BIS-ANILINE DERIVATIVES USEFUL AS POTASSIUM CHANNELS MODULATORS | 4SC AG (DE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009973-A1 | Phenylenediamine derivatives N-substituted with benzyl- or heteroarylmethyl- groups | PAH, PNMT, OPRM1 | CA1 2457/4885CA2 1332/4885ADRA2A 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.